English

NURIX THERAPEUTICS, INC.

EDGAR

NRIX Quarterly report (10-Q) · filed 2026-10-13

Annual consolidated revenue for 2025: about USD 83.98M, using the latest reported figures. The previous period, 2024, was about USD 54.55M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

673 million USD

2026 Q3 · USD

Exact inputs and evidence

Revenue: 673064000 USD Source

Operating margin

83.12%

2026 Q3 · %

Exact inputs and evidence

Operating Income: 559451000 USD Source
Revenue: 673064000 USD Source

Operating cash flow

616 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 447144000 USD Source
Operating Cash Flow: -168487000 USD Source

Free cash flow

614 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 447144000 USD Source
Operating Cash Flow: -168487000 USD Source
Capital Expenditure: 4373000 USD Source
Capital Expenditure: 2981000 USD Source

Cash and cash equivalents: 720 million USD 2026-08-31 Source
Exact value

720242000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 109 million shares 2026-08-31 Source
Exact value

109200394 shares

Reported share-count change

42.05% · 32.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

76872686 shares · 2025-08-31· Source
109200394 shares · 2026-08-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

702 million USD

2025-09-01 – 2026-08-31

Exact inputs and evidence

Revenue: 83980000 USD · 2024-12-01 – 2025-11-30 Source
Revenue: 70403000 USD · 2024-12-01 – 2025-08-31 Source
Revenue: 6252000 USD · 2025-12-01 – 2026-02-28 Source
Revenue: 9043000 USD · 2026-03-01 – 2026-05-31 Source
Revenue: 673064000 USD · 2026-06-01 – 2026-08-31 Source

Net income

295 million USD

2025-09-01 – 2026-08-31

Exact inputs and evidence

Net income: -264457000 USD · 2024-12-01 – 2025-11-30 Source
Net income: -186236000 USD · 2024-12-01 – 2025-08-31 Source
Net income: -87174000 USD · 2025-12-01 – 2026-02-28 Source
Net income: -89535000 USD · 2026-03-01 – 2026-05-31 Source
Net income: 549807000 USD · 2026-06-01 – 2026-08-31 Source

Operating cash flow

379 million USD

2025-09-01 – 2026-08-31

Exact inputs and evidence

Operating cash flow: -249465000 USD · 2024-12-01 – 2025-11-30 Source
Operating cash flow: -181633000 USD · 2024-12-01 – 2025-08-31 Source
Operating cash flow: -71914000 USD · 2025-12-01 – 2026-02-28 Source
Operating cash flow: -168487000 USD · 2025-12-01 – 2026-05-31 Source
Operating cash flow: -71914000 USD · 2025-12-01 – 2026-02-28 Source
Operating cash flow: 447144000 USD · 2025-12-01 – 2026-08-31 Source
Operating cash flow: -168487000 USD · 2025-12-01 – 2026-05-31 Source

Capital expenditure

9.5 million USD

2025-09-01 – 2026-08-31

Exact inputs and evidence

Capital expenditure: 14002000 USD · 2024-12-01 – 2025-11-30 Source
Capital expenditure: 8871000 USD · 2024-12-01 – 2025-08-31 Source
Capital expenditure: 1045000 USD · 2025-12-01 – 2026-02-28 Source
Capital expenditure: 2981000 USD · 2025-12-01 – 2026-05-31 Source
Capital expenditure: 1045000 USD · 2025-12-01 – 2026-02-28 Source
Capital expenditure: 4373000 USD · 2025-12-01 – 2026-08-31 Source
Capital expenditure: 2981000 USD · 2025-12-01 – 2026-05-31 Source

Free cash flow

370 million USD

2025-09-01 – 2026-08-31

Exact inputs and evidence

Operating cash flow: -249465000 USD · 2024-12-01 – 2025-11-30 Source
Operating cash flow: -181633000 USD · 2024-12-01 – 2025-08-31 Source
Operating cash flow: -71914000 USD · 2025-12-01 – 2026-02-28 Source
Operating cash flow: -168487000 USD · 2025-12-01 – 2026-05-31 Source
Operating cash flow: -71914000 USD · 2025-12-01 – 2026-02-28 Source
Operating cash flow: 447144000 USD · 2025-12-01 – 2026-08-31 Source
Operating cash flow: -168487000 USD · 2025-12-01 – 2026-05-31 Source
Capital expenditure: 14002000 USD · 2024-12-01 – 2025-11-30 Source
Capital expenditure: 8871000 USD · 2024-12-01 – 2025-08-31 Source
Capital expenditure: 1045000 USD · 2025-12-01 – 2026-02-28 Source
Capital expenditure: 2981000 USD · 2025-12-01 – 2026-05-31 Source
Capital expenditure: 1045000 USD · 2025-12-01 – 2026-02-28 Source
Capital expenditure: 4373000 USD · 2025-12-01 – 2026-08-31 Source
Capital expenditure: 2981000 USD · 2025-12-01 – 2026-05-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-13.

Financial data available through: 2025-11-30.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-11-30
Operating income: 7 of 11 periods available· newest 2025-11-30
Net income: 7 of 11 periods available· newest 2025-11-30
Operating cash flow: 7 of 11 periods available· newest 2025-11-30
Capital expenditure: 7 of 11 periods available· newest 2025-11-30
Total assets: 7 of 11 periods available· newest 2025-11-30
Total liabilities: 7 of 11 periods available· newest 2025-11-30
Current assets: 7 of 11 periods available· newest 2025-11-30
Current liabilities: 7 of 11 periods available· newest 2025-11-30
Cash and cash equivalents: 7 of 11 periods available· newest 2025-11-30
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-11-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+54%

Prior period

USD 54.55 million

2023-12-01 – 2024-11-30
Current period

USD 83.98 million

2024-12-01 – 2025-11-30

Exact inputs and evidence

83980000 − 54549000 = 29431000 USD

54549000 USD · 2023-12-01 – 2024-11-30
Inspect prior input Prior source
83980000 USD · 2024-12-01 – 2025-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Year-over-year change in Revenue: 29431000 USD Concept: fundies:Revenue Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 83980000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1260480 Filing: 000154959526000016 Input fundies:Revenue: 54549000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1261136 Filing: 000154959526000016
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 70.89 million

Prior period

−USD 193.57 million

2023-12-01 – 2024-11-30
Current period

−USD 264.46 million

2024-12-01 – 2025-11-30

Exact inputs and evidence

-264457000 − -193569000 = -70888000 USD

-193569000 USD · 2023-12-01 – 2024-11-30
Inspect prior input Prior source
-264457000 USD · 2024-12-01 – 2025-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Year-over-year change in Net income: -70888000 USD Concept: fundies:NetIncome Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -264457000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1965751 Filing: 000154959526000016 Input fundies:NetIncome: -193569000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1966525 Filing: 000154959526000016
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 76.88 million

Prior period

−USD 172.58 million

2023-12-01 – 2024-11-30
Current period

−USD 249.47 million

2024-12-01 – 2025-11-30

Exact inputs and evidence

-249465000 − -172584000 = -76881000 USD

-172584000 USD · 2023-12-01 – 2024-11-30
Inspect prior input Prior source
-249465000 USD · 2024-12-01 – 2025-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Year-over-year change in Operating cash flow: -76881000 USD Concept: fundies:OperatingCashFlow Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -249465000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1427748 Filing: 000154959526000016 Input fundies:OperatingCashFlow: -172584000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1428400 Filing: 000154959526000016
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+51%

Prior period

USD 9.27 million

2023-12-01 – 2024-11-30
Current period

USD 14 million

2024-12-01 – 2025-11-30

Exact inputs and evidence

14002000 − 9273000 = 4729000 USD

9273000 USD · 2023-12-01 – 2024-11-30
Inspect prior input Prior source
14002000 USD · 2024-12-01 – 2025-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Year-over-year change in Capital expenditure: 4729000 USD Concept: fundies:CapitalExpenditure Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 14002000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1434539 Filing: 000154959526000016 Input fundies:CapitalExpenditure: 9273000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1435129 Filing: 000154959526000016
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2024-12-01 – 2025-11-30

Revenue USD 83.98 million 100% of revenue
Operating costs Derived USD 369.65 million 440% of revenue
Operating income −USD 285.67 million −340% of revenue
Tax, interest and other Derived −USD 21.21 million −25% of revenue
Net income −USD 264.46 million −315% of revenue

Cash

Operating cash flow −USD 249.47 million −297% of revenue
Capital expenditure USD 14 million 17% of revenue
Free cash flow Derived −USD 263.47 million −314% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 171% of revenue.
2020 Operating loss: operating costs were 465% of revenue.
2021 Operating loss: operating costs were 496% of revenue.
2022 Operating loss: operating costs were 576% of revenue.
2023 Operating loss: operating costs were 301% of revenue.
2024 Operating loss: operating costs were 491% of revenue.
2025 Operating loss: operating costs were 440% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2018-12-01 – 2019-11-30	31115000	53351000 Derived	-22236000	-537000 Derived	-21699000	-1050000 Derived	Source 2018-12-01 – 2019-11-30: 31115000 USD Inspect Revenue Open source 2018-12-01 – 2019-11-30: -22236000 USD Inspect Operating Income Open source 2018-12-01 – 2019-11-30: -21699000 USD Inspect Net Income Open source 2018-12-01 – 2019-11-30: 601000 USD Inspect Operating Cash Flow Open source 2018-12-01 – 2019-11-30: 1651000 USD Inspect Capital Expenditure Open source
2020 2019-12-01 – 2020-11-30	17820000	82803000 Derived	-64983000	-21741000 Derived	-43242000	-4633000 Derived	Source 2019-12-01 – 2020-11-30: 17820000 USD Inspect Revenue Open source 2019-12-01 – 2020-11-30: -64983000 USD Inspect Operating Income Open source 2019-12-01 – 2020-11-30: -43242000 USD Inspect Net Income Open source 2019-12-01 – 2020-11-30: -80000 USD Inspect Operating Cash Flow Open source 2019-12-01 – 2020-11-30: 4553000 USD Inspect Capital Expenditure Open source
2021 2020-12-01 – 2021-11-30	29750000	147636000 Derived	-117886000	-692000 Derived	-117194000	-90026000 Derived	Source 2020-12-01 – 2021-11-30: 29750000 USD Inspect Revenue Open source 2020-12-01 – 2021-11-30: -117886000 USD Inspect Operating Income Open source 2020-12-01 – 2021-11-30: -117194000 USD Inspect Net Income Open source 2020-12-01 – 2021-11-30: -84365000 USD Inspect Operating Cash Flow Open source 2020-12-01 – 2021-11-30: 5661000 USD Inspect Capital Expenditure Open source
2022 2021-12-01 – 2022-11-30	38627000	222494000 Derived	-183867000	-3507000 Derived	-180360000	-172051000 Derived	Source 2021-12-01 – 2022-11-30: 38627000 USD Inspect Revenue Open source 2021-12-01 – 2022-11-30: -183867000 USD Inspect Operating Income Open source 2021-12-01 – 2022-11-30: -180360000 USD Inspect Net Income Open source 2021-12-01 – 2022-11-30: -159807000 USD Inspect Operating Cash Flow Open source 2021-12-01 – 2022-11-30: 12244000 USD Inspect Capital Expenditure Open source
2023 2022-12-01 – 2023-11-30	76987000	232050000 Derived	-155063000	-11115000 Derived	-143948000	-89766000 Derived	Source 2022-12-01 – 2023-11-30: 76987000 USD Inspect Revenue Open source 2022-12-01 – 2023-11-30: -155063000 USD Inspect Operating Income Open source 2022-12-01 – 2023-11-30: -143948000 USD Inspect Net Income Open source 2022-12-01 – 2023-11-30: -81365000 USD Inspect Operating Cash Flow Open source 2022-12-01 – 2023-11-30: 8401000 USD Inspect Capital Expenditure Open source
2024 2023-12-01 – 2024-11-30	54549000	267576000 Derived	-213027000	-19458000 Derived	-193569000	-181857000 Derived	Source 2023-12-01 – 2024-11-30: 54549000 USD Inspect Revenue Open source 2023-12-01 – 2024-11-30: -213027000 USD Inspect Operating Income Open source 2023-12-01 – 2024-11-30: -193569000 USD Inspect Net Income Open source 2023-12-01 – 2024-11-30: -172584000 USD Inspect Operating Cash Flow Open source 2023-12-01 – 2024-11-30: 9273000 USD Inspect Capital Expenditure Open source
2025 2024-12-01 – 2025-11-30	83980000	369646000 Derived	-285666000	-21209000 Derived	-264457000	-263467000 Derived	Source 2024-12-01 – 2025-11-30: 83980000 USD Inspect Revenue Open source 2024-12-01 – 2025-11-30: -285666000 USD Inspect Operating Income Open source 2024-12-01 – 2025-11-30: -264457000 USD Inspect Net Income Open source 2024-12-01 – 2025-11-30: -249465000 USD Inspect Operating Cash Flow Open source 2024-12-01 – 2025-11-30: 14002000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 84M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-11-30	Revenue	31115000	Revenue: 31115000 Open source
20202020-11-30	Revenue	17820000	Revenue: 17820000 Open source
20212021-11-30	Revenue	29750000	Revenue: 29750000 Open source
20222022-11-30	Revenue	38627000	Revenue: 38627000 Open source
20232023-11-30	Revenue	76987000	Revenue: 76987000 Open source
20242024-11-30	Revenue	54549000	Revenue: 54549000 Open source
20252025-11-30	Revenue	83980000	Revenue: 83980000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

54% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-11-30	Year over year	No prior comparable period	Revenue: 31115000 Open source
20202020-11-30	Year over year	-42.7%	Revenue: 17820000 Open source Revenue: 31115000 Open source
20212021-11-30	Year over year	66.9%	Revenue: 29750000 Open source Revenue: 17820000 Open source
20222022-11-30	Year over year	29.8%	Revenue: 38627000 Open source Revenue: 29750000 Open source
20232023-11-30	Year over year	99.3%	Revenue: 76987000 Open source Revenue: 38627000 Open source
20242024-11-30	Year over year	-29.1%	Revenue: 54549000 Open source Revenue: 76987000 Open source
20252025-11-30	Year over year	54%	Revenue: 83980000 Open source Revenue: 54549000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -340.2% 2025

Net margin -314.9% 2025

Free cash flow margin -313.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-11-30	Operating margin	-71.5%	Operating Income: -22236000 Open source Revenue: 31115000 Open source
20202020-11-30	Operating margin	-364.7%	Operating Income: -64983000 Open source Revenue: 17820000 Open source
20212021-11-30	Operating margin	-396.3%	Operating Income: -117886000 Open source Revenue: 29750000 Open source
20222022-11-30	Operating margin	-476%	Operating Income: -183867000 Open source Revenue: 38627000 Open source
20232023-11-30	Operating margin	-201.4%	Operating Income: -155063000 Open source Revenue: 76987000 Open source
20242024-11-30	Operating margin	-390.5%	Operating Income: -213027000 Open source Revenue: 54549000 Open source
20252025-11-30	Operating margin	-340.2%	Operating Income: -285666000 Open source Revenue: 83980000 Open source
20192019-11-30	Net margin	-69.7%	Net Income: -21699000 Open source Revenue: 31115000 Open source
20202020-11-30	Net margin	-242.7%	Net Income: -43242000 Open source Revenue: 17820000 Open source
20212021-11-30	Net margin	-393.9%	Net Income: -117194000 Open source Revenue: 29750000 Open source
20222022-11-30	Net margin	-466.9%	Net Income: -180360000 Open source Revenue: 38627000 Open source
20232023-11-30	Net margin	-187%	Net Income: -143948000 Open source Revenue: 76987000 Open source
20242024-11-30	Net margin	-354.9%	Net Income: -193569000 Open source Revenue: 54549000 Open source
20252025-11-30	Net margin	-314.9%	Net Income: -264457000 Open source Revenue: 83980000 Open source
20192019-11-30	Free cash flow margin	-3.4%	Revenue: 31115000 Open source Operating Cash Flow: 601000 Open source Capital Expenditure: 1651000 Open source
20202020-11-30	Free cash flow margin	-26%	Revenue: 17820000 Open source Operating Cash Flow: -80000 Open source Capital Expenditure: 4553000 Open source
20212021-11-30	Free cash flow margin	-302.6%	Revenue: 29750000 Open source Operating Cash Flow: -84365000 Open source Capital Expenditure: 5661000 Open source
20222022-11-30	Free cash flow margin	-445.4%	Revenue: 38627000 Open source Operating Cash Flow: -159807000 Open source Capital Expenditure: 12244000 Open source
20232023-11-30	Free cash flow margin	-116.6%	Revenue: 76987000 Open source Operating Cash Flow: -81365000 Open source Capital Expenditure: 8401000 Open source
20242024-11-30	Free cash flow margin	-333.4%	Revenue: 54549000 Open source Operating Cash Flow: -172584000 Open source Capital Expenditure: 9273000 Open source
20252025-11-30	Free cash flow margin	-313.7%	Revenue: 83980000 Open source Operating Cash Flow: -249465000 Open source Capital Expenditure: 14002000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -249.5M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-11-30	Operating cash flow	601000	Operating Cash Flow: 601000 Open source
20202020-11-30	Operating cash flow	-80000	Operating Cash Flow: -80000 Open source
20212021-11-30	Operating cash flow	-84365000	Operating Cash Flow: -84365000 Open source
20222022-11-30	Operating cash flow	-159807000	Operating Cash Flow: -159807000 Open source
20232023-11-30	Operating cash flow	-81365000	Operating Cash Flow: -81365000 Open source
20242024-11-30	Operating cash flow	-172584000	Operating Cash Flow: -172584000 Open source
20252025-11-30	Operating cash flow	-249465000	Operating Cash Flow: -249465000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -263.5M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-11-30	Free cash flow	-1050000	Operating Cash Flow: 601000 Open source Capital Expenditure: 1651000 Open source
20202020-11-30	Free cash flow	-4633000	Operating Cash Flow: -80000 Open source Capital Expenditure: 4553000 Open source
20212021-11-30	Free cash flow	-90026000	Operating Cash Flow: -84365000 Open source Capital Expenditure: 5661000 Open source
20222022-11-30	Free cash flow	-172051000	Operating Cash Flow: -159807000 Open source Capital Expenditure: 12244000 Open source
20232023-11-30	Free cash flow	-89766000	Operating Cash Flow: -81365000 Open source Capital Expenditure: 8401000 Open source
20242024-11-30	Free cash flow	-181857000	Operating Cash Flow: -172584000 Open source Capital Expenditure: 9273000 Open source
20252025-11-30	Free cash flow	-263467000	Operating Cash Flow: -249465000 Open source Capital Expenditure: 14002000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

21.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-11-30	Liabilities / assets	121.6%	Total Liabilities: 53567000 Open source Total Assets: 44048000 Open source
20202020-11-30	Liabilities / assets	26.8%	Total Liabilities: 106074000 Open source Total Assets: 396343000 Open source
20212021-11-30	Liabilities / assets	28.2%	Total Liabilities: 134469000 Open source Total Assets: 476771000 Open source
20222022-11-30	Liabilities / assets	27.1%	Total Liabilities: 113063000 Open source Total Assets: 416759000 Open source
20232023-11-30	Liabilities / assets	43.6%	Total Liabilities: 155105000 Open source Total Assets: 355598000 Open source
20242024-11-30	Liabilities / assets	21.3%	Total Liabilities: 142350000 Open source Total Assets: 669343000 Open source
20252025-11-30	Liabilities / assets	21.7%	Total Liabilities: 149388000 Open source Total Assets: 688135000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.02× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-11-30	Current assets / current liabilities	2.44×	Current Assets: 39354000 Open source Current Liabilities: 16137000 Open source
20202020-11-30	Current assets / current liabilities	6.7×	Current Assets: 298434000 Open source Current Liabilities: 44539000 Open source
20212021-11-30	Current assets / current liabilities	4.7×	Current Assets: 311118000 Open source Current Liabilities: 66258000 Open source
20222022-11-30	Current assets / current liabilities	4.51×	Current Assets: 318449000 Open source Current Liabilities: 70655000 Open source
20232023-11-30	Current assets / current liabilities	3.4×	Current Assets: 295503000 Open source Current Liabilities: 86958000 Open source
20242024-11-30	Current assets / current liabilities	6.46×	Current Assets: 619387000 Open source Current Liabilities: 95854000 Open source
20252025-11-30	Current assets / current liabilities	7.02×	Current Assets: 606819000 Open source Current Liabilities: 86471000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2018-12-01 – 2019-11-30	−USD 21.7 million Exact value Exact value: -21699000 USD 2018-12-01 – 2019-11-30: -21699000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NURIX THERAPEUTICS, INC. · 2019-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Net Income: -21699000 USD Concept: fundies:NetIncome Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ANetIncome&period=2019-11-30&surface=latest&period_type=duration&start=2018-12-01&unit=USD&dimensions= Input fundies:NetIncome: -21699000 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#3822161 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.	USD 601,000 Exact value Exact value: 601000 USD 2018-12-01 – 2019-11-30: 601000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NURIX THERAPEUTICS, INC. · 2019-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Operating Cash Flow: 601000 USD Concept: fundies:OperatingCashFlow Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3AOperatingCashFlow&period=2019-11-30&surface=latest&period_type=duration&start=2018-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 601000 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2634213 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.	USD 1.65 million Exact value Exact value: 1651000 USD 2018-12-01 – 2019-11-30: 1651000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NURIX THERAPEUTICS, INC. · 2019-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Capital Expenditure: 1651000 USD Concept: fundies:CapitalExpenditure Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ACapitalExpenditure&period=2019-11-30&surface=latest&period_type=duration&start=2018-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1651000 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2662439 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.	−USD 1.05 million Calculation and evidence 601000 − 1651000 USD Exact free cash flow: -1050000 USD 2018-12-01 – 2019-11-30: 601000 USD · Inspect Operating Cash Flow · Source 2018-12-01 – 2019-11-30: 1651000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NURIX THERAPEUTICS, INC. · 2019-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Free cash flow: -1050000 USD Concept: free-cash-flow Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 601000 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2634213 Filing: 000156459022003007 Input fundies:CapitalExpenditure: 1651000 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2662439 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.
2020 2019-12-01 – 2020-11-30	−USD 43.24 million Exact value Exact value: -43242000 USD 2019-12-01 – 2020-11-30: -43242000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NURIX THERAPEUTICS, INC. · 2020-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Net Income: -43242000 USD Concept: fundies:NetIncome Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ANetIncome&period=2020-11-30&surface=latest&period_type=duration&start=2019-12-01&unit=USD&dimensions= Input fundies:NetIncome: -43242000 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#3820292 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.	−USD 80,000 Exact value Exact value: -80000 USD 2019-12-01 – 2020-11-30: -80000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NURIX THERAPEUTICS, INC. · 2020-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Operating Cash Flow: -80000 USD Concept: fundies:OperatingCashFlow Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3AOperatingCashFlow&period=2020-11-30&surface=latest&period_type=duration&start=2019-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80000 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2632270 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.	USD 4.55 million Exact value Exact value: 4553000 USD 2019-12-01 – 2020-11-30: 4553000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NURIX THERAPEUTICS, INC. · 2020-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Capital Expenditure: 4553000 USD Concept: fundies:CapitalExpenditure Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ACapitalExpenditure&period=2020-11-30&surface=latest&period_type=duration&start=2019-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4553000 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2660540 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.	−USD 4.63 million Calculation and evidence -80000 − 4553000 USD Exact free cash flow: -4633000 USD 2019-12-01 – 2020-11-30: -80000 USD · Inspect Operating Cash Flow · Source 2019-12-01 – 2020-11-30: 4553000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NURIX THERAPEUTICS, INC. · 2020-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Free cash flow: -4633000 USD Concept: free-cash-flow Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -80000 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2632270 Filing: 000156459022003007 Input fundies:CapitalExpenditure: 4553000 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm#2660540 Filing: 000156459022003007 The citation records this snapshot. The page link may show a newer release later.
2021 2020-12-01 – 2021-11-30	−USD 117.19 million Exact value Exact value: -117194000 USD 2020-12-01 – 2021-11-30: -117194000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NURIX THERAPEUTICS, INC. · 2021-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Net Income: -117194000 USD Concept: fundies:NetIncome Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ANetIncome&period=2021-11-30&surface=latest&period_type=duration&start=2020-12-01&unit=USD&dimensions= Input fundies:NetIncome: -117194000 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000021/nrix-20221130.htm#2119225 Filing: 000154959523000021 The citation records this snapshot. The page link may show a newer release later.	−USD 84.37 million Exact value Exact value: -84365000 USD 2020-12-01 – 2021-11-30: -84365000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NURIX THERAPEUTICS, INC. · 2021-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Operating Cash Flow: -84365000 USD Concept: fundies:OperatingCashFlow Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3AOperatingCashFlow&period=2021-11-30&surface=latest&period_type=duration&start=2020-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -84365000 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000021/nrix-20221130.htm#1422528 Filing: 000154959523000021 The citation records this snapshot. The page link may show a newer release later.	USD 5.66 million Exact value Exact value: 5661000 USD 2020-12-01 – 2021-11-30: 5661000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NURIX THERAPEUTICS, INC. · 2021-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Capital Expenditure: 5661000 USD Concept: fundies:CapitalExpenditure Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ACapitalExpenditure&period=2021-11-30&surface=latest&period_type=duration&start=2020-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5661000 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000021/nrix-20221130.htm#1431788 Filing: 000154959523000021 The citation records this snapshot. The page link may show a newer release later.	−USD 90.03 million Calculation and evidence -84365000 − 5661000 USD Exact free cash flow: -90026000 USD 2020-12-01 – 2021-11-30: -84365000 USD · Inspect Operating Cash Flow · Source 2020-12-01 – 2021-11-30: 5661000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NURIX THERAPEUTICS, INC. · 2021-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Free cash flow: -90026000 USD Concept: free-cash-flow Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -84365000 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000021/nrix-20221130.htm#1422528 Filing: 000154959523000021 Input fundies:CapitalExpenditure: 5661000 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000021/nrix-20221130.htm#1431788 Filing: 000154959523000021 The citation records this snapshot. The page link may show a newer release later.
2022 2021-12-01 – 2022-11-30	−USD 180.36 million Exact value Exact value: -180360000 USD 2021-12-01 – 2022-11-30: -180360000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NURIX THERAPEUTICS, INC. · 2022-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Net Income: -180360000 USD Concept: fundies:NetIncome Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ANetIncome&period=2022-11-30&surface=latest&period_type=duration&start=2021-12-01&unit=USD&dimensions= Input fundies:NetIncome: -180360000 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000016/nrix-20241130.htm#1994859 Filing: 000154959525000016 The citation records this snapshot. The page link may show a newer release later.	−USD 159.81 million Exact value Exact value: -159807000 USD 2021-12-01 – 2022-11-30: -159807000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NURIX THERAPEUTICS, INC. · 2022-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Operating Cash Flow: -159807000 USD Concept: fundies:OperatingCashFlow Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3AOperatingCashFlow&period=2022-11-30&surface=latest&period_type=duration&start=2021-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -159807000 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000016/nrix-20241130.htm#1442626 Filing: 000154959525000016 The citation records this snapshot. The page link may show a newer release later.	USD 12.24 million Exact value Exact value: 12244000 USD 2021-12-01 – 2022-11-30: 12244000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NURIX THERAPEUTICS, INC. · 2022-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Capital Expenditure: 12244000 USD Concept: fundies:CapitalExpenditure Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ACapitalExpenditure&period=2022-11-30&surface=latest&period_type=duration&start=2021-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12244000 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000016/nrix-20241130.htm#1449369 Filing: 000154959525000016 The citation records this snapshot. The page link may show a newer release later.	−USD 172.05 million Calculation and evidence -159807000 − 12244000 USD Exact free cash flow: -172051000 USD 2021-12-01 – 2022-11-30: -159807000 USD · Inspect Operating Cash Flow · Source 2021-12-01 – 2022-11-30: 12244000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NURIX THERAPEUTICS, INC. · 2022-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Free cash flow: -172051000 USD Concept: free-cash-flow Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -159807000 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000016/nrix-20241130.htm#1442626 Filing: 000154959525000016 Input fundies:CapitalExpenditure: 12244000 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000016/nrix-20241130.htm#1449369 Filing: 000154959525000016 The citation records this snapshot. The page link may show a newer release later.
2023 2022-12-01 – 2023-11-30	−USD 143.95 million Exact value Exact value: -143948000 USD 2022-12-01 – 2023-11-30: -143948000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NURIX THERAPEUTICS, INC. · 2023-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Net Income: -143948000 USD Concept: fundies:NetIncome Period: 2022-12-01 to 2023-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ANetIncome&period=2023-11-30&surface=latest&period_type=duration&start=2022-12-01&unit=USD&dimensions= Input fundies:NetIncome: -143948000 USD (2022-12-01 to 2023-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1967300 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	−USD 81.37 million Exact value Exact value: -81365000 USD 2022-12-01 – 2023-11-30: -81365000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NURIX THERAPEUTICS, INC. · 2023-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Operating Cash Flow: -81365000 USD Concept: fundies:OperatingCashFlow Period: 2022-12-01 to 2023-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3AOperatingCashFlow&period=2023-11-30&surface=latest&period_type=duration&start=2022-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -81365000 USD (2022-12-01 to 2023-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1429053 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	USD 8.4 million Exact value Exact value: 8401000 USD 2022-12-01 – 2023-11-30: 8401000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NURIX THERAPEUTICS, INC. · 2023-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Capital Expenditure: 8401000 USD Concept: fundies:CapitalExpenditure Period: 2022-12-01 to 2023-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ACapitalExpenditure&period=2023-11-30&surface=latest&period_type=duration&start=2022-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8401000 USD (2022-12-01 to 2023-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1435719 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	−USD 89.77 million Calculation and evidence -81365000 − 8401000 USD Exact free cash flow: -89766000 USD 2022-12-01 – 2023-11-30: -81365000 USD · Inspect Operating Cash Flow · Source 2022-12-01 – 2023-11-30: 8401000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NURIX THERAPEUTICS, INC. · 2023-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Free cash flow: -89766000 USD Concept: free-cash-flow Period: 2022-12-01 to 2023-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -81365000 USD (2022-12-01 to 2023-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1429053 Filing: 000154959526000016 Input fundies:CapitalExpenditure: 8401000 USD (2022-12-01 to 2023-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1435719 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.
2024 2023-12-01 – 2024-11-30	−USD 193.57 million Exact value Exact value: -193569000 USD 2023-12-01 – 2024-11-30: -193569000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NURIX THERAPEUTICS, INC. · 2024-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Net Income: -193569000 USD Concept: fundies:NetIncome Period: 2023-12-01 to 2024-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ANetIncome&period=2024-11-30&surface=latest&period_type=duration&start=2023-12-01&unit=USD&dimensions= Input fundies:NetIncome: -193569000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1966525 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	−USD 172.58 million Exact value Exact value: -172584000 USD 2023-12-01 – 2024-11-30: -172584000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NURIX THERAPEUTICS, INC. · 2024-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Operating Cash Flow: -172584000 USD Concept: fundies:OperatingCashFlow Period: 2023-12-01 to 2024-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3AOperatingCashFlow&period=2024-11-30&surface=latest&period_type=duration&start=2023-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -172584000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1428400 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	USD 9.27 million Exact value Exact value: 9273000 USD 2023-12-01 – 2024-11-30: 9273000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NURIX THERAPEUTICS, INC. · 2024-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Capital Expenditure: 9273000 USD Concept: fundies:CapitalExpenditure Period: 2023-12-01 to 2024-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ACapitalExpenditure&period=2024-11-30&surface=latest&period_type=duration&start=2023-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9273000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1435129 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	−USD 181.86 million Calculation and evidence -172584000 − 9273000 USD Exact free cash flow: -181857000 USD 2023-12-01 – 2024-11-30: -172584000 USD · Inspect Operating Cash Flow · Source 2023-12-01 – 2024-11-30: 9273000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NURIX THERAPEUTICS, INC. · 2024-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Free cash flow: -181857000 USD Concept: free-cash-flow Period: 2023-12-01 to 2024-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -172584000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1428400 Filing: 000154959526000016 Input fundies:CapitalExpenditure: 9273000 USD (2023-12-01 to 2024-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1435129 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.
2025 2024-12-01 – 2025-11-30	−USD 264.46 million Exact value Exact value: -264457000 USD 2024-12-01 – 2025-11-30: -264457000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Net Income: -264457000 USD Concept: fundies:NetIncome Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ANetIncome&period=2025-11-30&surface=latest&period_type=duration&start=2024-12-01&unit=USD&dimensions= Input fundies:NetIncome: -264457000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1965751 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	−USD 249.47 million Exact value Exact value: -249465000 USD 2024-12-01 – 2025-11-30: -249465000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Operating Cash Flow: -249465000 USD Concept: fundies:OperatingCashFlow Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3AOperatingCashFlow&period=2025-11-30&surface=latest&period_type=duration&start=2024-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -249465000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1427748 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	USD 14 million Exact value Exact value: 14002000 USD 2024-12-01 – 2025-11-30: 14002000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Capital Expenditure: 14002000 USD Concept: fundies:CapitalExpenditure Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595/explain?concept=fundies%3ACapitalExpenditure&period=2025-11-30&surface=latest&period_type=duration&start=2024-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14002000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1434539 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.	−USD 263.47 million Calculation and evidence -249465000 − 14002000 USD Exact free cash flow: -263467000 USD 2024-12-01 – 2025-11-30: -249465000 USD · Inspect Operating Cash Flow · Source 2024-12-01 – 2025-11-30: 14002000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NURIX THERAPEUTICS, INC. · 2025-11-30 NURIX THERAPEUTICS, INC. (edgar:1549595) Free cash flow: -263467000 USD Concept: free-cash-flow Period: 2024-12-01 to 2025-11-30 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1549595?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -249465000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1427748 Filing: 000154959526000016 Input fundies:CapitalExpenditure: 14002000 USD (2024-12-01 to 2025-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm#1434539 Filing: 000154959526000016 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

38 filings · 1,851 latest values · 1,851 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001549595, 1549595, NRIX, edgar:1549595

Also known as NURIX THERAPEUTICS, INC., Nurix Therapeutics, Inc., Nurix, Inc.

NURIX THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2024-12-01 – 2025-11-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation